United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged

United Therapeutics highlighted its performance in the first half of 2026 and expressed expectations for the approval of ralinepag and Tyvaso IPF in 2027.

View Source Article ↗

AI CATALYST SCORE75 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

Diagnosed At	Ticker	AI Score	Tier
2026-08-30 22:01:39	UTHR	75	Mid	View Report →
2026-08-15 04:53:05	UTHR	40	Row	View Report →
2026-08-14 03:31:29	UTHR	40	Row	View Report →

United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged

UTHR Analysis History (Last 30 Days)